Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy
详细信息 查看全文
- 作者：Kathrin Strasser-Weippla ; kathrin.strasserweippl@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Nora Horickb ; nhorick@partners.org" class="auth_mail" title="E-mail the corresponding author ; Ian E. Smithc ; ian.smith@rmh.nhs.uk" class="auth_mail" title="E-mail the corresponding author ; Joyce O'Shaughnessyd ; Joyce.OShaughnessy@usoncology.com" class="auth_mail" title="E-mail the corresponding author ; Bent Ejlertsene ; ejlertsen@dadlnet.dk" class="auth_mail" title="E-mail the corresponding author ; Frances Boylef ; franb@bigpond.net.au" class="auth_mail" title="E-mail the corresponding author ; Aman U. Buzdarg ; abuzdar@mdanderson.org" class="auth_mail" title="E-mail the corresponding author ; Pierre Fumoleauh ; pfumoleau@cgfl.fr" class="auth_mail" title="E-mail the corresponding author ; William Gradishari ; WGradishar@nmff.org" class="auth_mail" title="E-mail the corresponding author ; Miguel Martinj ; mmartin@geicam.org" class="auth_mail" title="E-mail the corresponding author ; Beverly Moyk ; bmoy@partners.org" class="auth_mail" title="E-mail the corresponding author ; Martine Piccart-Gebhartl ; martine.piccart@bordet.be" class="auth_mail" title="E-mail the corresponding author ; Kathleen I. Pritchardm ; kathy.pritchard@sunnybrook.ca" class="auth_mail" title="E-mail the corresponding author ; Deborah Lindquistn ; deborah.lindquist@usoncology.com" class="auth_mail" title="E-mail the corresponding author ; Erica Rappoldo ; mprcer@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Dianne M. Finkelsteinb ; dfinkelstein@partners.org" class="auth_mail" title="E-mail the corresponding author ; Paul E. Gossk ; pgoss@partners.org" class="auth_mail" title="E-mail the corresponding author ; pgoss@mgh.havard.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Lapatinib ; Early breast cancer ; Adjuvant ; Hormone receptor
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：56
- 期：Complete
- 页码：85-92
- 全文大小：669 K
文摘
- class="listitem" id="list_ulist0010">
- class="label">•
Efficacy of lapatinib might be predicted by hormone receptor expression.
- class="label">•
Lapatinib benefits human epidermal growth factor receptor 2 (HER2)+hormone receptor (HR)– early breast cancer patients not receiving trastuzumab.
- class="label">•
When trastuzumab is not offered lapatinib might be used in HER2+HR– breast cancer.
- class="label">•
Numbers-needed-to-treat should be presented for patient subgroups of large studies.